

Pharmacological Chaperoning of Nicotinic Acetylcholine Receptors Reduces the Endoplasmic Reticulum Stress Response^S

Rahul Srinivasan, Christopher I. Richards, Cheng Xiao, Doreen Rhee, Rigo Pantoja, Dennis A. Dougherty, Julie M. Miwa, and Henry A. Lester

Divisions of Biology (R.S., C.I.R., C.X., D.R., R.P., J.M.M., H.A.L.) and Chemistry and Chemical Engineering (D.A.D.), California Institute of Technology, Pasadena, California

Received January 13, 2012; accepted February 28, 2012

ABSTRACT

We report the first observation that endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) can decrease when a central nervous system drug acts as an intracellular pharmacological chaperone for its classic receptor. Transient expression of $\alpha 4\beta 2$ nicotinic receptors (nAChRs) in Neuro-2a cells induced the nuclear translocation of activating transcription factor 6 (ATF6), which is part of the UPR. Cells were exposed for 48 h to the full agonist nicotine, the partial agonist cytisine, or the competitive antagonist dihydro- β -erythroidine; we also tested mutant nAChRs that readily exit the ER. Each of these four manipulations increased Sec24D-enhanced green fluorescent protein fluorescence of condensed ER exit sites and attenuated translocation of ATF6-enhanced green fluorescent protein to the nucleus. However, we found no correlation among the manipulations regarding other tested parameters

[i.e., changes in nAChR stoichiometry ($\alpha 4_2\beta 2_3$ versus $\alpha 4_3\beta 2_2$), changes in ER and trans-Golgi structures, or the degree of nAChR up-regulation at the plasma membrane]. The four manipulations activated 0 to 0.4% of nAChRs, which shows that activation of the nAChR channel did not underlie the reduced ER stress. Nicotine also attenuated endogenously expressed ATF6 translocation and phosphorylation of eukaryotic initiation factor 2 α in mouse cortical neurons transfected with $\alpha 4\beta 2$ nAChRs. We conclude that, when nicotine accelerates ER export of $\alpha 4\beta 2$ nAChRs, this suppresses ER stress and the UPR. Suppression of a sustained UPR may explain the apparent neuroprotective effect that causes the inverse correlation between a person's history of tobacco use and susceptibility to developing Parkinson's disease. This suggests a novel mechanism for neuroprotection by nicotine.

This work was supported by the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant NS11756]; the National Institutes of Health National Institute on Aging [Grant AG033954]; National Institutes of Health National Institute on Drug Abuse Kirschstein National Research Service Award [Grant DA030877] (to C.I.R.); Targacept; Louis and Janet Fletcher; the Michael J. Fox Foundation; a California Tobacco-Related Disease Research Program postdoctoral fellowship [Grant 18FT-0066] (to R.S.); a Beckman Institute fellowship (to C.I.R.); and a California Tobacco-Related Disease Research Program New Investigator Award [Grant 19KT-0032] (to J.M.M.).

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.

<http://dx.doi.org/10.1124/mol.112.077792>.

^S The online version of this article (available at <http://molpharm.aspetjournals.org>) contains supplemental material.

Introduction

Nicotine seems to cause at least part of the well documented inverse correlation between a person's history of smoking and his or her susceptibility to developing Parkinson's disease (Hernán et al., 2002; Lester et al., 2009; Quik et al., 2011). The use of smoked or smoke-cured tobacco has no medical justification. Therefore, it is essential to understand the mechanistic basis for the apparent neuroprotective action of nicotine.

Nicotine binds to and activates neuronal nicotinic acetylcholine receptors (nAChRs), a family of ligand-gated ion channels comprising homopentameric and heteropentameric

ABBREVIATIONS: ATF6, activating transcription factor 6; BT, bleedthrough; CHOP, C/EBP homologous protein; DH β E, dihydro- β -erythroidine; eCFP, enhanced cyan fluorescent protein; eGFP, enhanced green fluorescent protein; eIF2 α , eukaryotic initiation factor 2 α ; p-eIF2 α , phosphorylated eukaryotic initiation factor 2 α ; ER, endoplasmic reticulum; ERES, endoplasmic reticulum exit site(s); W_{high} , fractional area of high-normalized Förster resonance energy transfer component; FRET, Förster resonance energy transfer; nAChR, nicotinic acetylcholine receptor; NFRET, normalized Förster resonance energy transfer; PERK, protein kinase RNA-like endoplasmic reticulum kinase; PM, plasma membrane; ROI, region of interest; SePhaChARNS, selective pharmacological chaperoning of acetylcholine receptor number and stoichiometry; TG, trans-Golgi; TGN, trans-Golgi network; TIRFM, total internal reflection fluorescence microscopy; UPR, unfolded protein response; wt, wild-type; GalT, galactosyl-transferase; FBS, fetal bovine serum; DMEM, Dulbecco's modified Eagle's medium; TBS, Tris-buffered saline.

combinations of α ($\alpha 2$ to $\alpha 10$) and β ($\beta 2$ to $\beta 4$) subunits (Gotti et al., 2007). The substantia nigra pars compacta dopaminergic neurons that degenerate in Parkinson's disease robustly express several nAChR receptor subtypes; some of these subtypes are substantially retained within the endoplasmic reticulum (ER) (Hill et al., 1993; Azam et al., 2002; Commons, 2008), rather than being efficiently trafficked to the plasma membrane (PM). We hypothesized that changes in the accumulation of nAChRs within the ER of dopaminergic neurons could influence a possible unfolded protein response (UPR)/ER stress response (Ron and Walter, 2007; Hetz and Glimcher, 2009). Long-term activation of the UPR can lead to apoptosis (Kim et al., 2006; Li et al., 2006). Post mortem studies have shown that dopaminergic neurons in patients with Parkinson's disease display increases in UPR markers (Hoozemans et al., 2007).

The best-known effect of chronic exposure to nicotine is up-regulation of nAChRs in vivo and in vitro, through cell-delimited, post-translational mechanisms (Schwartz and Kellar, 1983; Peng et al., 1994; Gopalakrishnan et al., 1997; Buisson and Bertrand, 2002; Sallette et al., 2005; Nashmi et al., 2007; Lester et al., 2009; Srinivasan et al., 2011). Emerging data suggest that selective pharmacological chaperoning of acetylcholine receptor number and stoichiometry (SePhaChARNS) by nicotine underlies nicotine-induced nAChR up-regulation (Kuryatov et al., 2005; Sallette et al., 2005; Lester et al., 2009; Miwa et al., 2011; Srinivasan et al., 2011). We hypothesized that SePhaChARNS also could attenuate the UPR and could partly explain the observed neuroprotective effects of nicotine in Parkinson's disease.

To test the ER stress/UPR hypothesis, we used the rich pharmacological features of $\alpha 4\beta 2$ nAChRs. nAChRs may be chaperoned by three distinct classes of $\alpha 4\beta 2$ ligands: full agonists (we chose nicotine itself), partial agonists (we chose cytosine), and antagonists [we chose dihydro- β -erythroidine (DH β E)] (Gopalakrishnan et al., 1997; Whiteaker et al., 1998; Kishi and Steinbach, 2006). We added a fourth, non-pharmacological manipulation: expression of a previously described $\beta 2^{\text{enhanced-ER-export}}$ mutant subunit (also called $\beta 2\text{-DM}$), which allows $\alpha 4\beta 2$ nAChRs to exit the ER efficiently (Srinivasan et al., 2011).

We found that exposure to all four manipulations did decrease the UPR, and this correlated well with increased ER exit sites (ERESs). The tested manipulations, however, displayed different effects at all other stages of receptor stabilization and trafficking. Our results point to the possibility that SePhaChARNS can decrease the UPR by increasing cargo export from the ER and altering the physiological features of the ER. The data establish that pharmacological chaperoning of a central nervous system receptor by a drug can decrease ER stress and attenuate the UPR, which is relevant to the apparent neuroprotective effects of nicotine in Parkinson's disease.

Materials and Methods

Reagents. PfuTurbo Cx Hotstart polymerase was purchased from Agilent Technologies (Santa Clara, CA). Mouse Neuro-2a cells (CCL-131) were obtained from American Type Culture Collection (Manassas, VA). Dulbecco's modified Eagle's medium (DMEM) with 4 mM L-glutamine, OptiMEM 1, Leibovitz L-15 imaging medium, Glutamax, Neurobasal medium, Lipofectamine 2000, and fetal bovine

serum (FBS) were purchased from Invitrogen (Carlsbad, CA). Nupherin-neuron was purchased from Enzo Life Sciences (Farmingdale, NY). Expressfect was purchased from Denville Scientific (South Plainfield, NJ). Poly-D-lysine-coated and uncoated 35-mm glass-bottomed imaging dishes (coverslip thickness, 0.19 mm) were obtained from MatTek (Ashland, MA). (-)-Nicotine hydrogen tartrate (Pubchem CID 6174), (-)-cytosine (Pubchem CID 22407), and DH β E (Pubchem CID 31762) were purchased from Sigma-Aldrich (St. Louis, MO). Pubchem can be accessed at <http://pubchem.ncbi.nlm.nih.gov>.

Plasmid Constructs. Mouse $\beta 2$ -eGFP and $\beta 2$ -mcherry were engineered as described previously (Nashmi et al., 2003). All other plasmids used in this study were described previously (Srinivasan et al., 2011). ATF6-eGFP was obtained from Dr. Ron Prywes (Columbia University, New York, NY) (Shen et al., 2005).

Cell Culture and Transfections. Mouse Neuro-2a cells were cultured by using standard tissue culture techniques and were maintained in 45% DMEM/45% OptiMEM/10% FBS. Plasmid concentrations used for transfection were as follows: 500 ng of each nAChR subunit, 75 ng of pCS2-mcherry, 250 ng of Sec24D constructs, 100 ng of pDsRed2-ER, 250 ng of GalT-eGFP, and 500 ng of ATF6-eGFP. A total of 90,000 cells were plated in poly-D-lysine-coated 35-mm glass-bottomed imaging dishes (MatTek). The following day, appropriate plasmid DNA concentrations were added to 4 μ l of Expressfect transfection reagent in 200 μ l of DMEM (final volume), and the mixture was incubated for 20 min at room temperature for formation of cationic lipid-DNA complexes. DMEM and DNA-lipid complexes were added to Neuro-2a cells in 1 ml of DMEM with 10% FBS and were incubated at 37°C for 4 h. Nicotine, cytosine, or DH β E was added at appropriate concentrations during the change of medium after 4 h of incubation with Expressfect-plasmid DNA complexes. Dishes were rinsed twice with DMEM, filled with 3 ml of DMEM with 10% FBS, and incubated at 37°C for 48 h.

Neuronal Transfection and Immunostaining. Cortical neurons were extracted from day 17 mouse embryos; 150,000 cells were plated in each 35-mm, poly-L-lysine-coated 35-mm glass-bottomed culture dish, in a solution containing Neurobasal medium, B27, and Glutamax supplemented with 3% equine serum. On day 4 of culture, neurons were treated with 1 μ M cytosine arabinoside. Neurons were maintained through 50% exchange with feeding medium (Neurobasal medium, B27, and Glutamax) twice per week. Neurons were transfected 5 days after plating, as follows: 1 μ g of each nAChR subunit plasmid was incubated with 20 μ g of Nupherin-neuron in 400 μ l of Neurobasal medium; 10 μ l of Lipofectamine 2000 was separately incubated for 15 min in 400 μ l of Neurobasal medium. The two solutions were combined, incubated for 45 min at room temperature, and then applied to cells. After 1 h of incubation, the total medium was replaced with 2 ml of fresh medium, with or without 0.1 μ M nicotine. For immunostaining, cultures were fixed the following day with 4% paraformaldehyde (10 min), permeabilized in 0.02% Tris-buffered saline (TBS)-Triton X-100 (15 min), and blocked with 10% goat serum (30 min). After two TBS washes, the appropriate primary antibody in 1% goat serum was applied overnight at 4°C. The following day, cultures were rinsed with TBS and incubated with 1% goat serum containing secondary antibody (1:5000, 30 min). Cells were rinsed with TBS and imaged immediately.

Antibodies. Immunostaining used ATF6 mouse monoclonal antibody (antibody 11909, 1:50 dilution; Abcam) and rabbit polyclonal antibodies to phosphorylated eukaryotic initiation factor 2 α (peIF2 α) and total eukaryotic initiation factor 2 α (eIF2 α) (antibodies 9721 and 5324, respectively, both at 1:200 dilution; Cell Signaling Technology, Danvers, MA). We used Alexa Fluor 488-labeled secondary antibodies (donkey anti-mouse and goat anti-rabbit antibodies; Invitrogen).

ATF6-eGFP Translocation Assay. An Eclipse C1si laser scanning confocal microscope equipped with a VC PlanApo, 63 \times , 1.4 numerical aperture, oil-immersion objective and a 32-anode photomultiplier tube (Nikon, Melville, NY) was used. All experiments were performed with live cells, 48 h after transfection, at 37°C in a stage-mounted culture dish incubator (Warner Instruments, Ham-

den, CT). Just before imaging, cell culture medium was replaced with phenol red-free, CO₂-independent, Leibovitz L-15 medium. Cells were effectively exposed to L-15 medium for ~20 to 40 min during imaging. The high amino acid concentrations in L-15 medium are unlikely to affect our observations during this relatively short period of exposure. For quantification of ATF6-eGFP translocation, the cell was focused to a plane where the nucleus was observed most clearly and full emission spectra were acquired after simultaneous excitation of eGFP and mcherry with 488-nm and 561-nm laser lines, respectively. Images were unmixed by using spectra from cells expressing only $\alpha 4$ -mcherry $\beta 2$ -wt nAChRs or only ATF6-eGFP. Regions of interest (ROIs) were manually demarcated for the nucleus and whole cell from the unmixed $\alpha 4$ -mcherry $\beta 2$ -wt image and then applied to the unmixed ATF6-eGFP image of the same cell. Ratios of integrated densities of ATF6-eGFP fluorescence in the nucleus and whole cell were obtained for each cell.

ERES Quantification. Neuro-2a cells were cotransfected with 500 ng each of $\alpha 4$ -mcherry and $\beta 2$ -wt nAChR subunit plasmids and 250 ng of the ERES marker Sec24D-eGFP plasmid. To control for distortions that can occur because of differences in cell size, all imaged cells were between 30 and 40 μ m in diameter. Each cell was focused to a plane where the maximal number of ERESs was observed. Sequential images of eGFP and mcherry fluorescence were obtained and linearly unmixed. For quantification, ERES ROIs were demarcated by using intensity-based threshold setting and were counted for each cell by using the particle analysis feature in ImageJ 1.44 (or a later version; <http://rsbweb.nih.gov/ij/>). The total Sec24D fluorescence in ERES, which constitutes the upper third of total Sec24D-eGFP fluorescence, was quantified for each cell. Total (integrated) Sec24D fluorescence in ERESs was calculated for each cell. Data are presented as the mean of data for 30 to 40 cells imaged under each condition. Error bars for ERES measurements indicate the S.E.M., and *p* values are based on a two-tailed *t* test.

Imaging and Quantification of Trans-Golgi Network and ER Fluorescence. Neuro-2a cells were transfected with $\alpha 4$ -eGFP (500 ng), $\beta 2$ -wt (500 ng), and GalT-mcherry (250 ng) or pDSred2-ER (100 ng) plasmids, and cells were incubated for 48 h with appropriate concentrations of nicotine, cytosine, or DH β E. Total internal reflection fluorescence microscopy (TIRFM) was used to observe the PM, trans-Golgi network (TGN), and ER. TIRFM images of 30 to 40 live cells were obtained for each experimental condition. TIRFM imaging was performed by using an inverted microscope (IX71; Olympus America, Center Valley, PA) equipped with an Olympus PlanApo 100 \times , 1.45 numerical aperture, oil-immersion objective and an actuated stage with a closed-loop controller (Thorlabs, Newton, NJ), to control the position of the fiber optic and TIRFM evanescent field illumination. $\alpha 4$ -eGFP was used for observation of $\alpha 4\beta 2$ nAChRs, whereas pDSred2-ER and GalT-mcherry markers (Schaub et al., 2006) were used to label the ER and TGN, respectively. eGFP and mcherry or DSred2 fluorophores were excited with a 488-nm, air-cooled, argon laser (IMA101040ALS; Melles Griot, Carlsbad, CA), and an Optosplit II image splitter (Cairn Research, Faversham, UK) was used to detect red and green fluorescence emissions simultaneously. Images were captured at 14-bit resolution with an iXON DU-897, back-illuminated, electron-multiplying charge-coupled device camera (Andor, South Windsor, CT). Sample exposure rate, percent laser transmission, and gain parameters were adjusted initially and then maintained constant across all samples for each imaging session. The 488-nm argon laser was linearly s-polarized, as revealed by using an achromatic 400- to 800-nm half-wave plate (AQWP05M-600; Thorlabs) (courtesy of Larry Wade).

We used ImageJ 1.44 software to quantify ER area and Metamorph software (Molecular Devices, Sunnyvale, CA) to quantify TGN number, size, and intensity. For quantification of ER area, the background was subtracted for each cell and the DSred2-ER fluorescence signal was subjected to manual threshold setting and demarcation to yield an ER ROI. The total ER area was measured for each cell, and a mean value for ER area was extracted for each experi-

mental group. TGN bodies were subjected to manual threshold-setting and demarcation. With the use of Metamorph software, number, size, and intensity statistics were extracted from demarcated ROIs. The Cairn image splitter plug-in for ImageJ was used for realignment of TIRFM images. TIRFM images were manually realigned by using distinct, obviously colocalized, organelle features in cellular footprints within the red and green emission windows.

Quantification of PM-Localized nAChRs. Details of the quantification method were described previously (Srinivasan et al., 2011). In brief, PM fluorescence was extracted as follows. Raw TIRFM images were converted to background-subtracted images, and the ER fluorescence was subjected to threshold-setting and selection. ER fluorescence was then subtracted from the original image to generate images with PM fluorescence signals. These procedures yielded a data set of several hundred thousand pixel intensities over the 15 to 50 cells in each experimental group. Fluorescence intensities are simply the sum of pixel values for either the PM, the ER, or the ER plus PM (obtained by using whole TIRFM footprint images, where "footprint" indicates the part of the cell that is in contact with the coverslip). Mean PM fluorescence intensity was derived by dividing the total fluorescence intensity for each experimental group by the number of imaged cells and was normalized to the intensity of untreated cells. To control for effects of cell size on average PM intensity, we imaged cells that had similar footprint areas. Cellular footprints with diameters of >50 μ m or <30 μ m were not imaged.

Whole-TIRFM footprint (ER plus PM)/ER fluorescence intensity ratios were used to determine the post-Golgi fraction of receptors. For PM integrated-density measurements, we used error bars to depict 99% confidence intervals based on a two-tailed *t* test, rather than plotting S.E.M. values (which would be indistinguishably small on the plots). Measurements from drug-treated cells were normalized to values for untreated cells imaged on the same day. DH β E TIRFM experiments were performed on a different day than nicotine and cytosine experiments.

Stoichiometry Monitored through Pixel-by-Pixel Normalized Förster Resonance Energy Transfer from Sensitized Acceptor Emission. General methods for pixel-by-pixel normalized Förster resonance energy transfer (NFRET) from sensitized acceptor emission were described previously (Moss et al., 2009; Son et al., 2009; Srinivasan et al., 2011). For the present NFRET experiments, Neuro-2a cells were transfected with GalT-eCFP, $\alpha 4$ -mcherry, and $\beta 2$ -eGFP subunit plasmids. Therefore, all $\beta 2$ subunits contained eGFP donors and all $\alpha 4$ subunits contained mcherry acceptors. The procedure yielded more-robust signals than those observed in our previous studies that used only fluorescent α subunits or only fluorescent β subunits. GalT-eCFP was used to label the TG/TGN (Schaub et al., 2006).

Cells transfected with $\alpha 4$ -mcherry $\beta 2$ -wt or $\alpha 4$ -wt $\beta 2$ -eGFP nAChRs were included in every imaging session, to control for pixel saturation and spectral bleedthrough (BT). Live cells were imaged by using an Eclipse C1si laser scanning confocal microscope. During image acquisition, cells were focused to a plane where the GalT-eCFP fluorescence was best observed. Images with emission spectra for eCFP, eGFP, and mcherry were acquired in 5-nm bins between 470 and 620 nm; 439-, 488-, and 561-nm laser lines were used to excite eCFP, eGFP, and mcherry, respectively. Images were linearly unmixed by using reference spectra for eCFP, eGFP, and mcherry with emission maxima at 477, 508, and 608 nm, respectively. Reference spectra were acquired from Neuro-2a cells transfected with GalT-eCFP, $\alpha 4$ -mcherry $\beta 2$ -wt, or $\alpha 4$ -wt $\beta 2$ -eGFP, during the same imaging session. Linear unmixing was used to separate all three emission spectra from each image. Linearly unmixed images were compiled into donor spectral BT stacks, acceptor BT stacks, and sample image stacks.

The PixFRET ImageJ plug-in was used to determine the eGFP and mcherry BT values and to calculate the net FRET (eq. 1) and NFRET values at each pixel. With the background and BT correc-

tions set, the net FRET value for each pixel (eq. 1) was calculated and the data were presented as 32-bit images. The net FRET value was divided by the square root of the eGFP and mcherry intensities (eq. 2) to yield the NFRET value at each pixel. FRET normalization was used to control for large differences in fluorophore expression within subcellular regions and between different cells in a dish.

$$nF = I_{\text{FRET}} - I_{\text{eGFP}} \times \text{BT}_{\text{eGFP}} - I_{\text{mcherry}} \times \text{BT}_{\text{mcherry}} \quad (1)$$

$$\text{NFRET} = \frac{I_{\text{FRET}} - I_{\text{eGFP}} \times \text{BT}_{\text{eGFP}} - I_{\text{mcherry}} \times \text{BT}_{\text{mcherry}}}{\sqrt{I_{\text{eGFP}} \times I_{\text{mcherry}}}} \quad (2)$$

where nF is net FRET, I_{FRET} is mcherry-sensitized emission with 488-nm excitation, I_{eGFP} is eGFP emission with 488-nm excitation, BT_{eGFP} is the spectral BT of eGFP emission into mcherry emission spectra at 488-nm excitation, I_{mcherry} is mcherry emission with 561-nm excitation, and $\text{BT}_{\text{mcherry}}$ is the spectral BT of mcherry emission into eGFP emission spectra at 561-nm excitation. I_{FRET} , I_{eGFP} , and I_{mcherry} were determined from Neuro-2a cells transfected with GalT-eCFP, $\alpha 4$ -mcherry, and $\beta 2$ -eGFP. BT_{eGFP} and $\text{BT}_{\text{mcherry}}$ values were determined from Neuro-2a cells transfected with $\alpha 4$ -wt plus $\beta 2$ -eGFP and $\alpha 4$ -mcherry plus $\beta 2$ -wt, respectively.

Histograms of NFRET (x -axis) versus the number of pixels (y -axis) for each imaged cell were compiled for either the whole cell sections or the TG/TGN ROIs, which were demarcated by using intensity-based threshold-setting for GalT-eCFP fluorescence. Frequency histograms obtained in this way (omitting values of 0) were merged for all cells in each experimental group and were fitted to two Gaussian components such that a minimal goodness-of-fit (R^2) value of 0.995 was achieved. NFRET histograms were fitted to Gaussian components, which yielded the total pixel area for either the A1 (low mean NFRET fit) or A2 (high mean NFRET fit) component. For quantitative measurements of stoichiometry, we compared the fractional area for the high-NFRET component (W_{high}) in each case, as given by eq. 3,

$$W_{\text{high}} = \frac{A2}{(A1 + A2)} \quad (3)$$

where W_{high} is the fractional area of the high-NFRET component, A1 is the area under the curve for the low mean NFRET Gaussian component, and A2 is the area under the curve for the high mean NFRET Gaussian component.

Because of variability resulting from cell passage number, we imaged untreated $\alpha 4$ -mcherry- plus $\beta 2$ -eGFP-transfected control cells on the same day, to evaluate the effects of drug exposure on stoichiometry. To provide further evidence that the two fitted NFRET components reflect nAChR stoichiometry, we manipulated receptor stoichiometry by transfecting biased ratios of $\alpha 4$ -mcherry and $\beta 2$ -eGFP nAChR subunit plasmids into Neuro-2a cells (see Supplemental Fig. 1). We verified that reducing the mole fraction of transfected $\beta 2$ -eGFP subunit cDNA from 0.67 to 0.5 and to 0.33 caused monotonic increases in W_{high} and mean NFRET (Supplemental Fig. 1C). The formal Gaussian fits (see Fig. 5 and Supplemental Fig. 1B) could arise either if each component contains a mixture of individual pixels that each contain a pure $\alpha 4_3\beta 2_2$ or $\alpha 4_2\beta 2_3$ population or if individual pixels contain a mixture of $\alpha 4_3\beta 2_2$ and $\alpha 4_2\beta 2_3$.

Patch-Clamp Recording. Neuro-2a cells were plated on 12-mm glass coverslips placed in 35-mm, plastic-bottomed, cell culture dishes. The following day, cells were transfected with 500 ng of $\alpha 4$ -eGFP and 500 ng of $\beta 2$ -wt nAChR subunit plasmids. Twenty-four to 48 h later, glass coverslips were transferred to dishes on the microscope stage. Green fluorescence was observed with an upright microscope (BX50WI; Olympus America) with UV illumination with appropriate excitation filters. Agonist-induced currents were tested at a holding potential of -65 mV by using a focal, relatively rapid, drug application system designed to minimize desensitization (Xiao

et al., 2009). We applied drugs from the lowest concentration to the highest concentration, at 3-min intervals, to minimize desensitization. Whole-cell patch-clamp recordings were performed with a MultiClamp 700B amplifier, a 1322 analog-to-digital converter, and pCLAMP 9.2 software (all from Molecular Devices). Data were sampled at 10 kHz and were filtered at 2 kHz.

The intrapipette solution contained 135 mM potassium gluconate, 5 mM KCl, 5 mM EGTA, 0.5 mM CaCl_2 , 10 mM HEPES, 2 mM Mg-ATP, and 0.1 mM GTP; the pH was adjusted to 7.2 with Tris base and the osmolarity was adjusted to 300 mOsm with sucrose. The extracellular solution contained 140 mM NaCl, 5 mM KCl, 2 mM CaCl_2 , 1 mM MgCl_2 , 10 mM HEPES, and 10 mM glucose; the pH was adjusted to 7.3 with Tris base. The Nernst potential for Cl^- in the intrapipette solution was -82.9 mV. The bath was continuously perfused with extracellular solution at room temperature ($23 \pm 1^\circ\text{C}$). The patch electrodes had resistances of 5 to 8 M Ω . The junction potential between the patch pipette and the bath solutions was adjusted to null just before a gigaohm seal was formed. Series resistance was monitored and compensated by 70 to 80% throughout recordings. Data were ignored if the series resistance (15–30 M Ω) changed by $>20\%$ during the recording session.

Results

Each of the Four Manipulations Inhibits Nuclear Translocation of ATF6. We hypothesized that nAChR expression and up-regulation could affect the ER stress response/UPR (Srinivasan et al., 2011). During the UPR, ATF6 is translocated from the ER to the Golgi and is cleaved by site 1 and site 2 proteases to release an N-terminal peptide. The N-terminal ATF6 peptide is translocated to the nucleus and initiates transcription of several target UPR genes that enhance ER function (Matsushita et al., 2002; Bommasamy et al., 2009; Maiuolo et al., 2011).

To test the effect of nAChR expression on nuclear ATF6 translocation, we used a previously reported ATF6 construct with an N-terminal eGFP fusion (ATF6-eGFP) (Shen and Prywes, 2005; Shen et al., 2005). Neuro-2a cells were transfected with either ATF6-eGFP alone or ATF6-eGFP and $\alpha 4$ -mcherry $\beta 2$ -wt nAChRs (Fig. 1A). We found that coexpression of $\alpha 4$ -mcherry $\beta 2$ -wt nAChRs increased nuclear ATF6-eGFP translocation (Fig. 1, A and B). For evaluation of whether the observed increase in ATF6-eGFP translocation to the nucleus was an artifact of DNA transfection or protein overexpression, Neuro-2a cells were cotransfected with ATF6-eGFP and $\alpha 4$ -mcherry, paired with either $\beta 2$ -wt or a previously described $\beta 2_{\text{enhanced-ER-export}}$ mutant subunit (also called $\beta 2$ -DM), which is known to undergo enhanced ER export (Srinivasan et al., 2011). Compared with $\alpha 4$ -mcherry $\beta 2$ -wt nAChRs, expression of $\alpha 4$ -mcherry $\beta 2_{\text{enhanced-ER-export}}$ mutants caused a 40% reduction in the ATF6-eGFP nuclear/whole-cell fluorescence ratio in the absence of nicotine (Fig. 1B).

In parallel experiments, Neuro-2a cells coexpressing ATF6-eGFP and $\alpha 4$ -mcherry $\beta 2$ -wt nAChRs were treated with nicotine, cytosine (0.1 μM , 48 h), or DH β E (10 or 100 μM , 48 h). Nicotine and cytosine caused $\sim 25\%$ reductions in the ATF6-eGFP nuclear/whole-cell fluorescence ratio (Fig. 1B), and both concentrations of DH β E reduced the ratio by $\sim 23\%$ (Fig. 1B). None of the tested ligands affected ATF6-eGFP translocation in the absence of nAChR coexpression (Fig. 1C).

Nicotine Inhibits Endogenous ATF6 Translocation and Prevents eIF2 α Phosphorylation in Primary Mouse Cortical Neurons. We sought to study the effects of




Fig. 1. Each of the four manipulations decreases ATF6 translocation in Neuro-2a cells. A, representative confocal images of Neuro-2a cells expressing $\alpha 4$ -mcherry $\beta 2$ -wt nAChRs plus ATF6-eGFP or only ATF6-eGFP. Scale bars, 10 μ m. B, ATF6-eGFP fluorescence intensity ratios (nucleus/whole cell section). Treatment conditions and transfected subunits are indicated on the x-axis. DM, double-mutant $\beta 2^{\text{enhanced-ER-export}}$ subunit. C, ATF6-eGFP fluorescence intensity ratios (nucleus/whole cell section) in the absence of coexpressed nAChRs. Drug treatments are indicated on the x-axis. The *p* values are based on a 2-tailed *t* test. **, *p* < 0.01; ***, *p* < 0.001. Data were obtained from 30 to 40 cells imaged for each condition. Nic, nicotine; Cyt, cytosine.

nicotine on the UPR in primary neurons in culture. Cells were transfected with $\alpha 4$ -mcherry $\beta 2$ -wt nAChRs and were separately immunostained for endogenous ATF6, total eIF2 α , or peIF2 α .

A total of 56% of $\alpha 4$ -mcherry $\beta 2$ -wt-expressing neurons showed nuclear ATF6 localization in the absence of nicotine (Fig. 2A), which decreased to 14% after 24-h treatment with 0.1 μ M nicotine. Compared with untreated cells, nicotine caused a significant 50% reduction in the ATF6 nuclear/whole-cell fluorescence ratio (Fig. 2B). peIF2 α and

total eIF2 α were localized to the nucleus and cytoplasm of all $\alpha 4$ -mcherry $\beta 2$ -wt-expressing neurons (Fig. 2A). Twenty-four-hour exposure to 0.1 μ M nicotine showed a trend toward reductions in whole-cell and cytoplasmic peIF2 α fluorescence (*p* = 0.06), whereas nuclear peIF2 α levels were significantly reduced, compared with untreated control cells (Fig. 2C). Nicotine did not affect total eIF2 α fluorescence within the cytoplasm or nucleus of neurons (Fig. 2D), which indicates specific nicotine-induced inhibition of eIF2 α phosphorylation.




Fig. 2. Nicotine inhibits ATF6 translocation to the nucleus and eIF2 α phosphorylation in mouse cortical neurons. A, representative confocal images of mouse cortical neurons expressing $\alpha 4$ -mcherry $\beta 2$ -wt, with immunostaining for endogenous ATF6, peIF2 α , or total eIF2 α (scale bars, 10 μ m). B, fluorescence intensity ratios for endogenously expressed ATF6, with and without 0.1 μ M nicotine (Nic) treatment for 24 h. C, nuclear fluorescence intensity for peIF2 α , with and without 0.1 μ M nicotine treatment for 24 h. D, fluorescence intensity for total eIF2 α . Bars show nicotine treatment conditions. All neurons in B, C, and D expressed transfected $\alpha 4$ -mcherry plus $\beta 2$ -wt subunits. The subcellular compartments imaged are indicated on the x-axis. The *p* values are based on a 2-tailed *t* test. *, *p* < 0.05; **, *p* < 0.01. Data were obtained from 20 to 30 cells imaged for each condition.




Fig. 3. Exposure to all three nicotinic ligands increases the formation of ERES. A, representative confocal images of a Neuro-2a cell expressing $\alpha 4$ -mcherry $\beta 2$ -wt nAChRs and Sec24D-eGFP (ERES marker). Scale bars, 10 μ m. B, image of the same cell with ERES demarcated for quantification. C, quantification of total Sec24D fluorescence in ERES per cell. Drug treatment conditions are indicated on the x-axis. Error bars indicate S.E.M. The p values are based on a 2-tailed t test. *, $p < 0.05$; **, $p < 0.01$. The graphs present total Sec24D fluorescence of ERES per cell, averaged for 30 to 40 cells imaged for each condition. Nic, nicotine; Cyt, cytosine.

Each of the Four Manipulations Increases ERES Formation. To understand the mechanistic basis for the effects of nicotinic ligands on the UPR, we studied the effects of each ligand on ERES formation. Neuro-2a cells were transfected with $\alpha 4$ -mcherry $\beta 2$ -wt nAChRs, and Sec24D-eGFP was used as a marker to quantify ERES (Fig. 3A). We quantified fluorescence from condensed Sec24D-eGFP ERES structures that contributed to the upper third of total Sec24D-eGFP fluorescence in each cell (Fig. 3B). All three nicotinic ligands caused significant 1.5- to 2-fold increases in the total Sec24D fluorescence in ERES per cell, compared

with untreated control cells (Fig. 3C). These data suggest that ligand-induced UPR inhibition arises, at least in part, from increased cargo exit from the ER. Previous data showed that replacement of the $\beta 2$ subunit by the $\beta 2_{\text{enhanced-ER-export}}$ subunit also enhanced the formation of ERES (Srinivasan et al., 2011). We separately measured the area and the number of ERES per cell for all drug treatment conditions, and we observed statistically significant differences (data not shown).

The Manipulations Have Diverse Effects on the Morphological Features of the ER and TGN. TIRFM can be used to determine the subcellular localization of fluorescent protein-labeled receptors at the cellular periphery (Richards et al., 2011). Those experiments showed that a majority of wt $\alpha 4\beta 2$ receptors were localized to the ER (Srinivasan et al., 2011). Here, we used TIRFM to quantify the effects of ligand-induced nAChR up-regulation on the ER and TGN architecture. For quantification, we used fluorescence from specific fluorescent protein-tagged markers of the ER (DSred2-ER) or the TGN (GalT-mcherry) in the presence of coexpressed $\alpha 4\beta 2$ nAChRs. Therefore, the results described here assessed the effects of the ligand- $\alpha 4\beta 2$ interaction on general ER and TGN morphological features.

In a first set of TIRFM experiments, Neuro-2a cells were cotransfected with $\alpha 4$ -eGFP $\beta 2$ -wt nAChRs and DSred2-ER (ER marker). Expressed $\alpha 4$ -eGFP $\beta 2$ -wt nAChRs colocalized almost completely with DSred2-ER fluorescence (Fig. 4A). We used DSred2-ER fluorescence to demarcate and to quantify the average area of peripheral ER. Compared with untreated control cells, nicotine exposure caused a 1.7-fold increase in the average ER area, whereas cytosine caused a significant ~ 1.4 -fold reduction and DH β E did not significantly affect the ER area (Fig. 4B).

In a second set of TIRFM experiments, Neuro-2a cells were cotransfected with $\alpha 4$ -eGFP $\beta 2$ -wt and GalT-mcherry to demarcate the TGN (Fig. 4C). In this case, we quantified the average number and intensity of GalT-mcherry-labeled TGN bodies. Nicotine caused a significant ~ 2 -fold increase in the




Fig. 4. The three nicotinic ligands have diverse effects on ER and TGN architecture. A, representative TIRFM images of a cell coexpressing $\alpha 4$ -eGFP $\beta 2$ -wt nAChRs and pDSred2-ER marker. The merged image shows nearly complete colocalization of fluorescence from nAChRs and DSred2-ER. Scale bars, 10 μ m. B, quantification of average ER area determined by using DSred2-ER fluorescence. Drug treatments are indicated on the x-axis. C, representative TIRFM images of a cell expressing $\alpha 4$ -eGFP $\beta 2$ -wt nAChRs and GalT-mcherry. The merged image shows colocalization of GalT-mcherry with nAChRs. Scale bars, 10 μ m. D, quantification of the number of TGN bodies observed by using GalT-mcherry under each treatment condition, as indicated on the x-axis. E, quantification of the average TGN body fluorescence intensity observed by using GalT-mcherry under each treatment condition, as indicated on the x-axis. Error bars indicate S.E.M. The p values are based on a 2-tailed t test. *, $p < 0.05$; **, $p < 0.01$. Data were obtained from 30 to 40 cells imaged for each condition. Nic, nicotine; Cyt, cytosine; NS, not significant.

average number of TGN bodies per cell, compared with untreated cells, whereas cytosine and DH β E failed to affect the number of TGN bodies significantly (Fig. 4D). In addition, nicotine exposure did not affect the TGN intensity, whereas cytosine and DH β E significantly reduced the average intensity of TGN bodies (Fig. 4E). These data show that receptor chaperoning by nicotine, cytosine, and DH β E alters the morphological features of the ER and the TGN in a ligand-dependent manner.

The Four Manipulations Have Diverse Effects on nAChR Stoichiometry. These experiments implemented an improved NFRET method for monitoring nAChR stoichiometry (see *Materials and Methods* and Supplemental Fig. 1). We tested the effects of the three ligands on the stoichiometry ($\alpha_4\beta_2\beta_3$ versus $\alpha_4\beta_3\beta_2$) of assembled pentameric nAChRs, primarily in organelles. The fractional area of the high-NFRET component (W_{high}) was used to quantify nAChRs with $\alpha_4\beta_3\beta_2$ stoichiometry. Neuro-2a cells were transfected with α_4 -mcherry, β_2 -eGFP, and a trans-Golgi (TG), TGN marker, GalT-eCFP. Whole-cell and TG, TGN W_{high} values for untreated cells were 0.46 and 0.47, respectively, whereas whole-cell and TG, TGN W_{high} values decreased to 0.26 and 0.20, respectively, in nicotine-treated cells (Fig. 5A). In contrast to nicotine-treated cells, cytosine-treated cells showed net increases in W_{high} values for the whole cell ($W_{\text{high}} = 0.70$) and the TG, TGN ($W_{\text{high}} = 0.58$), compared with untreated control cells (Fig. 5A). DH β E did

not affect nAChR stoichiometry at concentrations ranging from 0.1 to 1 μM , but 10 μM DH β E increased the whole-cell W_{high} to 0.55 and increased the TG, TGN W_{high} to 0.63 (Fig. 5A). It should be noted that, compared with untreated, nicotine-treated, or cytosine-treated cells, treatment with either 10 or 100 μM DH β E produced a 3- to 5-fold reduction in the number of NFRET-positive pixels for the whole cell and TG, TGN (Fig. 5B).

These results demonstrate that nicotine and cytosine stabilize the assembly of $\alpha_4\beta_2\beta_3$ and $\alpha_4\beta_3\beta_2$ receptors, respectively, whereas DH β E weakly favors the assembly of $\alpha_4\beta_3\beta_2$ receptors. Previous data showed that replacement of the β_2 subunit with the $\beta_2^{\text{enhanced-ER-export}}$ subunit also stabilized the $\alpha_4\beta_2\beta_3$ stoichiometry (Srinivasan et al., 2011). All four manipulations produced changes in stoichiometry before export of receptors from the ER to the Golgi.

The Tested Agonist Concentrations Minimally Activate $\alpha_4\beta_2$ nAChRs. Because the observed effects of the agonists nicotine and cytosine on the cellular secretory pathway occurred at 0.1 μM , we sought to determine whether, and to what extent, this agonist concentration activates $\alpha_4\beta_2$ nAChRs. Whole-cell electrophysiological responses to focal nicotine and cytosine puffs were measured in Neuro-2a cells expressing α_4 -eGFP β_2 -wt nAChRs. Figure 6A shows representative traces with 0.1 μM nicotine or cytosine. Measured current amplitudes were normalized to the maximal current amplitude obtained through puffing of 500 μM nicotine (Fig.




Fig. 5. The three nicotinic ligands have diverse effects on $\alpha_4\beta_2$ nAChR stoichiometry. A, NFRET measurements were made by using α_4 -mcherry and β_2 -eGFP subunits transfected into Neuro-2a cells. Columns indicate the ROIs (whole cell or TG, TGN), and rows indicate drug treatment conditions. For each graph, the blue curve is the overall fit and dashed Gaussian curves are individual fits. W_{high} , corresponding to the $\alpha_4\beta_3\beta_2$ stoichiometry, is shown for each graph. B, representative NFRET images of Neuro-2a cells. Drug treatments are indicated for each cell. Calibration bars are from zero to 20%. Scale bars, 5 μm .




Fig. 6. The three nicotinic ligands have diverse effects on PM-localized $\alpha 4 \beta 2$ nAChRs. A, representative traces showing whole-cell currents induced by puffs of 0.1 and 500 μ M nicotine or 0.1 μ M cytosine and 500 μ M nicotine. B, representative TIRFM images of cells expressing $\alpha 4$ -eGFP $\beta 2$ -wt nAChRs with treatment with the indicated drugs for 48 h. Scale bars, 10 μ m. C, bar graph showing normalized PM fluorescence intensity from TIRFM images, normalized as described in *Materials and Methods*. Drug treatment conditions are shown on the x-axis. Error bars indicate 99% confidence intervals, which show that all differences are highly significant. D, footprint/ER ratios from TIRFM images. Drug treatment conditions are shown on the x-axis. Error bars indicate relative S.E. Data were obtained from 30 to 40 cells imaged for each condition. Nic, nicotine; Cyt, cytosine.

6A). With 0.1 μ M nicotine, we observed nicotine-evoked currents that were $0.44 \pm 0.07\%$ ($n = 4$) of maximal currents induced by 500 μ M nicotine. In the case of cytosine, 0.1 μ M activated $<0.1\%$ ($n = 7$) of maximal currents induced by 500 μ M nicotine. These data indicate that the effects of nicotine and cytosine on nAChR stoichiometry are likely to be independent of nAChR activation and ion flux.

The Four Manipulations Have Diverse Effects on Up-regulation of PM nAChRs. We used TIRFM to quantify the effects of nicotine, cytosine, and DH β E on nAChRs at the PM of Neuro-2a cells. Pixel-by-pixel TIRFM quantification is a direct measure of PM-localized receptors (Srinivasan et al., 2011). In addition, whole-footprint/ER-localized nAChR fluorescence ratios (footprint/ER ratios) provide quantitative measures of nAChRs in the PM versus the peripheral ER (Srinivasan et al., 2011). For these experiments, cells were transfected with $\alpha 4$ -eGFP $\beta 2$ -wt, and $\alpha 4$ -eGFP fluorescence was used to quantify nAChRs. Figure 6B shows representative TIRFM images of nAChR fluorescence after 48-h exposure to each drug.

Compared with untreated control cells, nicotine and cytosine caused 2- and 3-fold increases, respectively, whereas DH β E caused a small but significant increase in PM-localized nAChRs (Fig. 6C). To address the possibility of distortions arising from differences in cell footprint size, we also analyzed the TIRFM data by summing pixel fluorescence values for all cells within an experimental group and dividing the result by the number of pixels imaged, to obtain the average fluorescence intensity per pixel. The trend among the three ligands resembled that depicted in Fig. 6C. Com-

pared with untreated cells, nicotine, cytosine, and DH β E increased average PM pixel fluorescence values by 1.4-, 1.85-, and 1.1-fold, respectively.

The footprint/ER ratio decreased by ~ 2 -fold after nicotine treatment, whereas cytosine- and DH β E-treated cells showed ~ 1.5 -fold increases in the footprint/ER ratio, compared with untreated cells (Fig. 6D). Previous data showed that replacement of the $\beta 2$ subunit with the $\beta 2^{\text{enhanced-ER-export}}$ subunit also markedly increased the footprint/ER ratio (Srinivasan et al., 2011).

Discussion

The data establish, for the first time, that pharmacological chaperoning of a central nervous system receptor by a drug can decrease ER stress and attenuate the UPR. Parkinson's disease is associated with increased ER stress/UPR in dopaminergic neurons. Upon persistent activation, the UPR can cause apoptosis (Silva et al., 2005; Hoozemans et al., 2007). Because nicotine is potentially neuroprotective in Parkinson's disease (Hernán et al., 2002; Lester et al., 2009; Quik et al., 2011), we assessed the subcellular effects of pharmacological chaperoning by nicotinic ligands. Table 1 summarizes data obtained for the four manipulations [three exemplar nicotinic ligands and nAChRs containing $\beta 2^{\text{enhanced-ER-export}}$ mutant subunits]. All four manipulations suppressed ATF6 translocation, which serves as a key sensor for ER stress and the UPR (Ron and Walter, 2007; Hetz and Glimcher, 2009; Maiuolo et al., 2011), but the only other consistent phenomenon was the increased total Sec24D fluorescence in ERES.

TABLE 1

The four manipulations all reduce ATF6 translocation and increase condensed ERES but have diverse effects on other aspects of $\alpha 4\beta 2$ stoichiometry, organelle structure, and PM up-regulation

Numbers indicate fold change compared with untreated cells. Arrows indicate the fold increase or decrease from observed values in untreated cells. Some of the data for $\beta 2$ -DM are from Srinivasan et al. (2011).

Tested Parameter	Nicotine	Cytisine	DH β E	$\beta 2$ -DM
ATF6 (nucleus/whole cell)	↓1.4	↓1.4	↓1.4	↓1.6
Total Sec24D fluorescence in ERES	↑1.9	↑2	↑2.1	↑2
Peripheral ER area	↑1.8	↓1.5	↓1.2	N.D.
nAChR footprint/ER ratio	↓2	↑2	↑1.5	↑2.3
No. of TGN bodies	↑2	N.E.	N.E.	N.D.
TGN intensity	N.E.	↓3	↓3	N.D.
Major stoichiometry	$\alpha 4_2\beta 2_3$	$\alpha 4_3\beta 2_2$	$\alpha 4_3\beta 2_2$	$\alpha 4_2\beta 2_3$
PM nAChRs	↑2	↑3	↑1.2	↑2.5

N.D., not done; N.E., no effect; ↑, increase; ↓, decrease.

Therefore, we suggest that increased ER exit of nAChRs underlies the suppression of ATF6 translocation.

Dopaminergic neurons show robust expression of several nAChR subtypes (Champtiaux et al., 2003) that are localized to the ER under physiological conditions (Hill et al., 1993; Commons, 2008). Therefore, nAChRs are in a key position to affect the ER stress response by influencing the exit of cargo from the ER. In the present experiments, ER stress was caused by expression of the $\alpha 4\beta 2$ nAChRs themselves (Fig. 1, A and B), but it is plausible to suggest that increasing the ER exit of nAChRs could reorganize the COPII vesicle population and relieve ER stress caused by other environmental or genetic factors. Dopaminergic neurons contain potentially toxic metabolites of dopamine (Ahmadi et al., 2008; Miyazaki and Asanuma, 2009) and relatively high intracellular Ca^{2+} levels (Surmeier et al., 2011). These factors probably lead to increased levels of ER stress under physiological conditions (Egawa et al., 2011). Additional ER stress in catecholaminergic cell lines and in cultured dopaminergic neurons occurs by means of dopaminergic toxins or the overexpression of α -synuclein, which is linked to Parkinson's disease (Ryu et al., 2002; Holtz and O'Malley, 2003; Thayanidhi et al., 2010).

Several points suggested that the enhanced ATF6 translocation was not related to mere nonspecific overexpression. First, transient expression of ATF6-eGFP alone did not cause ATF6 translocation to the nucleus (Fig. 1B), and nicotinic ligands did not influence ATF6 localization (Fig. 1C). Second, nAChRs containing mutant $\beta 2$ subunits with enhanced ER export prevented ATF6 translocation, even in the absence of nicotine (Fig. 1B). Third, our experiments used a well characterized expression system in Neuro-2a cells, which express membrane proteins at rather lower levels, compared with more-commonly studied human embryonic kidney 293 cells (Moss et al., 2009). Likewise, neurons typically express transfected genes at only modest levels. It should be noted that, in most of our experiments, two or three $\alpha 4$ subunits per receptor contained a fluorescent protein label, which enabled us to identify nAChR-expressing Neuro-2a cells or neurons. Previous experiments with both cultured Neuro-2a cells and knock-in mice indicated that nAChRs containing such labeled $\alpha 4$ subunits were normal in every way studied (Nashmi et al., 2003, 2007; Fonck et al., 2009; Son et al., 2009). We cannot rule out the possibility that a large intracellular fluorophore in the $\alpha 4$ subunit can affect nAChR assembly, thereby enhancing an ER stress response.

Nicotine also inhibited ATF6 translocation in primary mouse cortical neurons transfected with $\alpha 4\beta 2$ nAChRs (Fig. 2, A and B). Therefore, the observed effects of nicotinic li-

gands on ATF6 localization occur in at least two cell types (neurons and a neuroblastoma cell line). These effects do not require ATF6 overexpression or the use of a non-native promoter to drive ATF6 gene expression. During the UPR, protein kinase RNA-like endoplasmic reticulum kinase (PERK) induces eIF2 α phosphorylation, which results in global inhibition of protein translation (Harding et al., 2000). A sustained increase in phosphorylated eIF2 α can cause C/EBP homologous protein (CHOP) mediated apoptosis (Harding et al., 2000; Scheuner et al., 2001; Galehdar et al., 2010). Previous reports described eIF2 α in the nucleus, which may function to regulate transcriptional and translational processes (Goldstein et al., 1999; DuRose et al., 2009; Tejada et al., 2009). We found that nicotine exposure significantly inhibited nuclear eIF2 α phosphorylation in $\alpha 4\beta 2$ -overexpressing neurons, without affecting total eIF2 α expression (Fig. 2, C and D). Nicotine also caused a nearly significant reduction of pEIF2 α in the cytoplasm ($p = 0.06$). Together, these data indicate that nicotinic ligands can inhibit the UPR via their interaction with nAChRs.

ERES formation is generally linked to some aspects of ER function. Chronic exposure to nicotine, cytosine, and DH β E increased the accumulation of Sec24D in ERES by ~2-fold in the presence of coexpressed nAChRs (Fig. 3C). In the context of Parkinson's disease neuroprotection, dopaminergic neurons exposed chronically to nicotine would increase the formation of ERES in a nAChR-dependent manner. We suggest that these events could cause a generalized exit of cargo from the ER, which would result in reduced signals for sensors of ER stress.

The specification of nAChR stoichiometry is a basic aspect of nAChR assembly that occurs before ER exit. Of the four manipulations tested, two (nicotine and inclusion of the $\beta 2_{\text{export-ER-export}}$ subunit) preferentially stabilized receptors with $\alpha 4_2\beta 2_3$ stoichiometry, whereas cytosine and DH β E preferentially stabilized the assembly of $\alpha 4_3\beta 2_2$ receptors (Fig. 5). Cytosine and DH β E bind strongly at the $\alpha 4$ - $\alpha 4$ interface that exists only in $\alpha 4_3\beta 2_2$ nAChRs, which provides the possible structural basis for the preferential stabilization of this stoichiometry (Mazzaferro et al., 2011). It is noteworthy that both types of stabilization increased ERES and suppressed ATF6 translocation. Apparently the nature of the subunit in the fifth or "auxiliary" position is not crucial for interactions with the COPII complex or for ER exit. Nicotine increased whereas cytosine reduced the area of peripheral ER, although both drugs decreased the UPR (Fig. 4B). Therefore, the attenuation of ATF6 translocation is apparently not sufficient to suppress the ER proliferation triggered by nAChRs. How-

ever, the attenuation of ATF6 translocation is sufficient to suppress ER proliferation when expression of a tail-anchored protein is sensed within the lipid bilayer (Maiuolo et al., 2011).

Events downstream from Golgi exit are not thought to influence the UPR markedly, and these events varied among the manipulations. Nicotine increased the number of TGN bodies per cell, whereas cytosine and DH β E reduced the average intensity of the TGN bodies (Fig. 4, D and E). Nicotine caused a \sim 2-fold increase in PM-localized nAChRs and a reduction in the footprint/ER integrated density ratio (Fig. 6, C and D). In contrast, cytosine treatment resulted in \sim 3.5-fold up-regulation of PM receptors and caused a \sim 2-fold increase in the footprint/ER ratio, whereas DH β E exposure led to no marked effects on these parameters (Fig. 6, C and D). These observations may indicate that the two nAChR stoichiometries stabilized by nicotinic ligands use distinct mechanisms for trafficking from Golgi to PM, through different interactions between the subunits' M3-M4 loops and cytoskeletal or trafficking proteins (Xu et al., 2006; Kabbani et al., 2007).

Our data (Fig. 6B) agree with earlier reports that DH β E produces comparatively minor up-regulation of PM α 4 β 2 nAChRs (Yang and Buccafusco, 1994; Gopalakrishnan et al., 1997) and that up-regulation requires DH β E concentrations of 10 to 100 μ M (Gopalakrishnan et al., 1997). Our data also suggest that DH β E shifts the nAChR stoichiometry toward the α 4 β 2 form, which is usually thought to have comparatively low acetylcholine sensitivity (reviewed by Miwa et al., 2011). A discrepant study by Buisson and Bertrand (2001) was performed with the same cell line as studied by Gopalakrishnan et al. (1997). However, the electrophysiological results reported by Buisson and Bertrand (2001) are unique in several ways; 10 nM DH β E produced up-regulation, and this was the most up-regulation measured among the ligands assessed. The concentration of 10 nM is a small fraction of the IC₅₀ for DH β E, and this treatment increased the fraction of high-sensitivity nAChRs. We cannot explain the differences between the DH β E effects reported by Buisson and Bertrand (2001) and the consistent DH β E effects reported by Yang and Buccafusco (1994) and Gopalakrishnan et al. (1997) and in the present study.

Nicotine may also regulate nAChR interactions with the ubiquitin-proteasome system (Rezvani et al., 2007, 2010). The present study shows reduction of ER stress at nicotine concentrations 500-fold lower than those required to suppress UPR pathways in tunicamycin-treated PC12 cells, for which direct actions of nicotine on the ubiquitin-proteasome system were suggested (Sasaya et al., 2008). PC12 cells lack α 4 β 2 nAChRs but express lower-affinity α 3 β 4 nAChRs, which may be subject to chaperoning at relatively high nicotine concentrations.

None of the four tested manipulations produce appreciable nAChR activation, which rules out mechanisms in which ion flux associated with receptor activation affects intracellular signaling cascades, receptor assembly, stoichiometry, and consequent effects on the UPR. Our electrophysiological experiments confirmed, in the transfected Neuro-2a cells under study, that 0.1 μ M nicotine or cytosine activated only 0.4% or $<$ 0.1% of the total receptor population, respectively (Fig. 6A). Moreover, the nicotine exposure used in our experiments probably desensitizes α 4 β 2 nAChRs. DH β E activated no re-

ceptors, and the mutant α 4 β 2_{enhanced-ER-export} receptors displayed no constitutive activity. These data agree with previous studies that showed that up-regulation is independent of surface nAChR activation (Salette et al., 2005; Corringer et al., 2006). Although these ligand concentrations activate no nAChRs when applied for a few seconds, these concentrations exceed, by factors of 10 to 100, the equilibrium binding dissociation constants measured with incubations of minutes to hours (Gopalakrishnan et al., 1997; Warpman et al., 1998; Whiteaker et al., 1998). Evidently, these ligand concentrations stabilize the formation of fully assembled ligand-receptor complexes, which can interact with ER-associated export machinery more readily than with ER-associated degradation.

Parkinson's disease becomes clinically apparent after a degenerative process has operated for a decade or longer. The apparent neuroprotective effects of smoking also begin decades before the clinical diagnosis (Ritz et al., 2007). Therefore, nicotine may exert a cumulative protective effect, which counteracts the cumulative degenerative mechanism. The data establish that pharmacological chaperoning of a central nervous system receptor by a drug can decrease ER stress and attenuate the UPR, and it is plausible to suggest that this mechanism exerts the required cumulative protective effect. Reductions in ER stress can occur without activation of PM nAChRs, which suggests a therapeutic strategy for neuroprotection without the potential for abuse. We do not yet know whether similar reductions in ER stress and UPR occur when nicotine interacts intracellularly with nAChRs at endogenous levels in the neurons of intact brains.

Acknowledgments

We thank Johannes Schwarz for discussion, Elisha D. W. Mackey for assistance with cloning, and Sheri McKinney for assistance with primary neuronal cultures.

Authorship Contributions

Participated in research design: Srinivasan, Richards, Pantoja, and Lester.

Conducted experiments: Srinivasan, Richards, Xiao, Rhee, and Pantoja.

Contributed new reagents or analytic tools: Srinivasan, Richards, and Miwa.

Performed data analysis: Srinivasan, Richards, Xiao, and Lester.

Wrote or contributed to the writing of the manuscript: Srinivasan, Richards, Dougherty, and Lester.

References

- Ahmadi FA, Grammatopoulos TN, Poczbott AM, Jones SM, Snell LD, Das M, and Zawada WM (2008) Dopamine selectively sensitizes dopaminergic neurons to rotenone-induced apoptosis. *Neurochem Res* **33**:886–901.
- Azam L, Winzer-Serhan UH, Chen Y, and Leslie FM (2002) Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. *J Comp Neurol* **444**:260–274.
- Bommasamy H, Back SH, Fagone P, Lee K, Meshinchi S, Vink E, Sriburi R, Frank M, Jackowski S, Kaufman RJ, et al. (2009) ATF6 α induces XBP1-independent expansion of the endoplasmic reticulum. *J Cell Sci* **122**:1626–1636.
- Buisson B and Bertrand D (2001) Chronic exposure to nicotine upregulates the human α 4 β 2 nicotinic acetylcholine receptor function. *J Neurosci* **21**:1819–1829.
- Buisson B and Bertrand D (2002) Nicotine addiction: the possible role of functional upregulation. *Trends Pharmacol Sci* **23**:130–136.
- Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Léna C, Clementi F, Moretti M, Rossi FM, Le Novère N, et al. (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knockout mice. *J Neurosci* **23**:7820–7829.
- Commons KG (2008) α 4 containing nicotinic receptors are positioned to mediate postsynaptic effects on 5-HT neurons in the rat dorsal raphe nucleus. *Neuroscience* **153**:851–859.
- Corringer PJ, Sallette J, and Changeux JP (2006) Nicotine enhances intracellular

- nicotinic receptor maturation: a novel mechanism of neural plasticity? *J Physiol Paris* **99**:162–171.
- DuRose JB, Scheuner D, Kaufman RJ, Rothblum LI, and Niwa M (2009) Phosphorylation of eukaryotic translation initiation factor 2 α coordinates rRNA transcription and translation inhibition during endoplasmic reticulum stress. *Mol Cell Biol* **29**:4295–4307.
- Egawa N, Yamamoto K, Inoue H, Hikawa R, Nishi K, Mori K, and Takahashi R (2011) The endoplasmic reticulum stress sensor, ATF6 α , protects against neurotoxin-induced dopaminergic neuronal death. *J Biol Chem* **286**:7947–7957.
- Fonck C, Nashmi R, Salas R, Zhou C, Huang Q, De Biasi M, Lester RA, and Lester HA (2009) Demonstration of functional $\alpha 4$ -containing nicotinic receptors in the medial habenula. *Neuropharmacology* **56**:247–253.
- Galehdar Z, Swan P, Fuerth B, Callaghan SM, Park DS, and Cregan SP (2010) Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA. *J Neurosci* **30**:16938–16948.
- Goldstein EN, Owen CR, White BC, and Rafols JA (1999) Ultrastructural localization of phosphorylated eIF2 α [eIF2 α (P)] in rat dorsal hippocampus during reperfusion. *Acta Neuropathol* **98**:493–505.
- Gopalakrishnan M, Molinari EJ, and Sullivan JP (1997) Regulation of human $\alpha 4\beta 2$ neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways. *Mol Pharmacol* **52**:524–534.
- Gotti C, Moretti M, Gaimarri A, Zanardi A, Clementi F, and Zoli M (2007) Heterogeneity and complexity of native brain nicotinic receptors. *Biochem Pharmacol* **74**:1102–1111.
- Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, and Ron D (2000) Regulated translation initiation controls stress-induced gene expression in mammalian cells. *Mol Cell* **6**:1099–1108.
- Hernán MA, Takkouche B, Caamaño-Isorna F, and Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. *Ann Neurol* **52**:276–284.
- Hetz C and Glimcher LH (2009) Fine-tuning of the unfolded protein response: assembling the IRE1 α interactome. *Mol Cell* **35**:551–561.
- Hill JA Jr, Zoli M, Bourgeois JP, and Changeux JP (1993) Immunocytochemical localization of a neuronal nicotinic receptor: the $\beta 2$ -subunit. *J Neurosci* **13**:1551–1568.
- Holtz WA and O'Malley KL (2003) Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. *J Biol Chem* **278**:19367–19377.
- Hoozemans JJ, van Haastert ES, Eikelenboom P, de Vos RA, Rozemuller JM, and Scheper W (2007) Activation of the unfolded protein response in Parkinson's disease. *Biochem Biophys Res Commun* **354**:707–711.
- Kabbani N, Woll MP, Levenson R, Lindstrom JM, and Changeux JP (2007) Intracellular complexes of the $\beta 2$ subunit of the nicotinic acetylcholine receptor in brain identified by proteomics. *Proc Natl Acad Sci USA* **104**:20570–20575.
- Kim R, Emi M, Tanabe K, and Murakami S (2006) Role of the unfolded protein response in cell death. *Apoptosis* **11**:5–13.
- Kishi M and Steinbach JH (2006) Role of the agonist binding site in up-regulation of neuronal nicotinic $\alpha 4\beta 2$ receptors. *Mol Pharmacol* **70**:2037–2044.
- Kuryatov A, Luo J, Cooper J, and Lindstrom J (2005) Nicotine acts as a pharmacological chaperone to up-regulate human $\alpha 4\beta 2$ acetylcholine receptors. *Mol Pharmacol* **68**:1839–1851.
- Lester HA, Xiao C, Srinivasan R, Son CD, Miwa J, Pantoja R, Banghart MR, Dougherty DA, Goate AM, and Wang JC (2009) Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery. *AAPS J* **11**:167–177.
- Li J, Lee B, and Lee AS (2006) Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. *J Biol Chem* **281**:7260–7270.
- Maiuolo J, Bulotta S, Verderio C, Benfante R, and Borgese N (2011) Selective activation of the transcription factor ATF6 mediates endoplasmic reticulum proliferation triggered by a membrane protein. *Proc Natl Acad Sci USA* **108**:7832–7837.
- Matsushita N, Okada H, Yasoshima Y, Takahashi K, Kiuchi K, and Kobayashi K (2002) Dynamics of tyrosine hydroxylase promoter activity during midbrain dopaminergic neuron development. *J Neurochem* **82**:295–304.
- Mazzafarro S, Benallegue N, Carbone A, Gasparri F, Vijayan R, Biggin PC, Moroni M, and Bermudez I (2011) Additional acetylcholine (ACh) binding site at $\alpha 4/\alpha 4$ interface of $\alpha 3\beta 2\alpha 4$ nicotinic receptor influences agonist sensitivity. *J Biol Chem* **286**:31043–31054.
- Miwa JM, Freedman R, and Lester HA (2011) Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. *Neuron* **70**:20–33.
- Miyazaki I and Asanuma M (2009) Approaches to prevent dopamine quinone-induced neurotoxicity. *Neurochem Res* **34**:698–706.
- Moss FJ, Imoukhuede PI, Scott K, Hu J, Jankowsky JL, Quick MW, and Lester HA (2009) GABA transporter function, oligomerization state, and anchoring: correlates with subcellularly resolved FRET. *J Gen Physiol* **134**:489–521.
- Nashmi R, Dickinson ME, McKinney S, Jareb M, Labarca C, Fraser SE, and Lester HA (2003) Assembly of $\alpha 4\beta 2$ nicotinic acetylcholine receptors assessed with functionally fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons. *J Neurosci* **23**:11554–11567.
- Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker P, Huang Q, McClure-Begley T, Lindstrom JM, Labarca C, et al. (2007) Chronic nicotine cell specifically upregulates functional $\alpha 4^*$ nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. *J Neurosci* **27**:8202–8218.
- Peng X, Gerzanich V, Anand R, Whiting PJ, and Lindstrom J (1994) Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. *Mol Pharmacol* **46**:523–530.
- Quik M, Bordia T, Huang L, and Perez X (2011) Targeting nicotinic receptors for Parkinson's disease therapy. *CNS Neurol Disord Drug Targets* **10**:651–658.
- Rezvani K, Teng Y, and De Biasi M (2010) The ubiquitin-proteasome system regulates the stability of neuronal nicotinic acetylcholine receptors. *J Mol Neurosci* **40**:177–184.
- Rezvani K, Teng Y, Shim D, and De Biasi M. (2007) Nicotine regulates multiple synaptic proteins by inhibiting proteasomal activity. *J Neurosci* **27**:10508–10519.
- Richards CI, Srinivasan R, Xiao C, Mackey ED, Miwa JM, and Lester HA (2011) Trafficking of $\alpha 4^*$ nicotinic receptors revealed by superecliptic phluorin: effects of a $\beta 4$ ALS-associated mutation and chronic exposure to nicotine. *J Biol Chem* **286**:31241–31249.
- Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, Ross GW, Strickland D, Van Den Eeden SK, and Gorell J (2007) Pooled analysis of tobacco use and risk of Parkinson disease. *Arch Neurol* **64**:990–997.
- Ron D and Walter P (2007) Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol* **8**:519–529.
- Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D, and Greene LA (2002) Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. *J Neurosci* **22**:10690–10698.
- Sallete J, Pons S, Devillers-Thiery A, Soudant M, Prado de Carvalho L, Changeux JP, and Corringier PJ (2005) Nicotine upregulates its own receptors through enhanced intracellular maturation. *Neuron* **46**:595–607.
- Sasaya H, Utsumi T, Shimoke K, Nakayama H, Matsumura Y, Fukunaga K, and Ikeuchi T (2008) Nicotine suppresses tunicamycin-induced, but not thapsigargin-induced, expression of GRP78 during ER stress-mediated apoptosis in PC12 cells. *J Biochem* **144**:251–257.
- Schaub BE, Berger B, Berger EG, and Rohrer J (2006) Transition of galactosyltransferase 1 from trans-Golgi cisterna to the trans-Golgi network is signal mediated. *Mol Biol Cell* **17**:5153–5162.
- Scheuner D, Song B, McEwen E, Liu C, Laybutt R, Gillespie P, Saunders T, Bonner-Weir S, and Kaufman RJ (2001) Translational control is required for the unfolded protein response and in vivo glucose homeostasis. *Mol Cell* **7**:1165–1176.
- Schwartz RD and Kellar KJ (1983) Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. *Science* **220**:214–216.
- Shen J and Prywes R (2005) ER stress signaling by regulated proteolysis of ATF6. *Methods* **35**:382–389.
- Shen J, Snapp EL, Lippincott-Schwartz J, and Prywes R (2005) Stable binding of ATF6 to BiP in the endoplasmic reticulum stress response. *Mol Cell Biol* **25**:921–932.
- Silva RM, Ries V, Oo TF, Yarygina O, Jackson-Lewis V, Ryu EJ, Lu PD, Marciniak SJ, Ron D, Przedborski S, et al. (2005) CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. *J Neurochem* **95**:974–986.
- Son CD, Moss FJ, Cohen BN, and Lester HA (2009) Nicotine normalizes intracellular subunit stoichiometry of nicotinic receptors carrying mutations linked to autosomal dominant nocturnal frontal lobe epilepsy. *Mol Pharmacol* **75**:1137–1148.
- Srinivasan R, Pantoja R, Moss FJ, Mackey ED, Son CD, Miwa J, and Lester HA (2011) Nicotine up-regulates $\alpha 4\beta 2$ nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning. *J Gen Physiol* **137**:59–79.
- Surmeier DJ, Guzman JN, Sanchez-Padilla J, and Goldberg JA (2011) The origins of oxidant stress in Parkinson's disease and therapeutic strategies. *Antioxid Redox Signal* **14**:1289–1301.
- Tejada S, Lobo MV, García-Villanueva M, Sacristán S, Pérez-Morgado MI, Salinas M, and Martín ME (2009) Eukaryotic initiation factors (eIF 2 α and 4E expression, localization, and phosphorylation in brain tumors. *J Histochem Cytochem* **57**:503–512.
- Thayanidhi N, Helm JR, Nycz DC, Bentley M, Liang Y, and Hay JC (2010) α -Synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. *Mol Biol Cell* **21**:1850–1863.
- Warpman U, Friberg L, Gillespie A, Hellström-Lindahl E, Zhang X, and Nordberg A (1998) Regulation of nicotinic receptor subtypes following chronic nicotine agonist exposure in M10 and SH-SY5Y neuroblastoma cells. *J Neurochem* **70**:2028–2037.
- Whiteaker P, Sharples CG, and Wonnacott S (1998) Agonist-induced up-regulation of $\alpha 4\beta 2$ nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition. *Mol Pharmacol* **53**:950–962.
- Xiao C, Nashmi R, McKinney S, Cai H, McIntosh JM, and Lester HA (2009) Chronic nicotine selectively enhances $\alpha 4\beta 2^*$ nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway. *J Neurosci* **29**:12428–12439.
- Xu J, Zhu Y, and Heinemann SF (2006) Identification of sequence motifs that target neuronal nicotinic receptors to dendrites and axons. *J Neurosci* **26**:9780–9793.
- Yang X and Buccafusco JJ (1994) Effect of chronic central treatment with the acetylcholine analog methylcarbamylcholine on cortical nicotinic receptors: correlation between receptor changes and behavioral function. *J Pharmacol Exp Ther* **271**:651–659.

Address correspondence to: Dr. Henry A. Lester, Division of Biology, MC 156-29, California Institute of Technology, Pasadena, CA 91125. E-mail: lester@caltech.edu